Screening intensity and biopsy burden diverged

WISDOM’s December 12, 2025 randomized trial of 28,372 women found risk-based screening met its safety threshold for stage IIB or later breast cancers. Biopsy rates did not fall overall. Fewer mammograms therefore did not automatically mean fewer invasive follow-up procedures. ^[1]

NIH’s January account explains the redistribution. Assessment combined genetics, health history and breast density. The highest-risk participants were assigned six-monthly imaging; lower-risk participants less. The intervention therefore changed who received screening resources, rather than simply reducing screening for everyone. ^[2]

Screening often departed from assignments, and participants disproportionately included college-educated White women, limiting generalizability. Meeting a noninferiority threshold also does not establish better survival than annual screening. ^[1]

A March 26, 2026 correction updated values throughout the participant-characteristics table. The corrected online report is the version consulted here; the correction notice does not announce a new screening trial or replace its original December event date. ^[3]

NIH also described counseling and prevention options for higher-risk participants. Implementation therefore includes risk communication alongside imaging capacity: matching services to assessed risk while preserving safety. The trial does not supply an individual screening schedule. ^[2]

About this item: Retrospective report. No first-hand reporting or independent testing is claimed. Corrections policy.